Novolyze raises funds to speed up development of surrogates
Surronov are non-pathogenic microorganisms mimicking the behaviour of pathogens such as Salmonella, Listeria and E. coli and can be manufactured in industrial quantities in dry form.
Novolyze’s products and services evaluate and validate food safety control processes.
It has developed ready-to-use ranges of surrogate microorganisms for a variety of products (milk powder, flour, meat, fish, pastries, juice, etc.).
Of the €2.2m, €1.2m came from private investors, family offices and business angels as well as public research programs and grants including the French government’s Investissement d’Avenir fund.
Novolyze generates 97% of its revenue outside France and since the Food Safety Modernization Act (FSMA) came into force in 2016, 60% has been contributed by the US.
The firm has 15 people at a manufacturing site in Dijon, a R&D facility at the Genopole in Evry and a subsidiary in the US.
Karim-Franck Khinouche, Novolyze’s CEO and founder, welcomed further investment from historical shareholders and new investors.
“Our ready-to-use products represent a major competitive advantage as we are able to offer effective control systems tailored to upstream risk processes in the agrifood industry and to enhance consumer protection even further, against the backdrop of the current focus on food safety.”
